CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性多发性骨髓瘤中 CAR-T 细胞治疗的成功序贯应用
英文原题：Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.
查看英文原题
Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文报告一例复发/难治性多发性骨髓瘤（RRMM）患者接受嵌合抗原受体（CAR）T 细胞治疗的病例。该患者接受 idecabtagene vicleucel（ide-cel，Abecma）后获得部分缓解，但缓解未能持久，随后接受 ciltacabtagene autoleucel（cilta-cel，Carvykti）。这两种 CAR-T 均靶向 B 细胞成熟抗原（BCMA），且序贯使用仍不常见，因此有关其序贯应用安全性和疗效的数据十分珍贵且具有参考价值。
展开英文摘要原文
We here report on a patient with relapsed-refractory multiple myeloma (RRMM) who received chimeric antigen receptor (CAR) T-cells (Ciltacabtagene Autoleucel, cilta-cel, Carvykti ) after achieving a partial but not durable remission with Idecabtagene Vicleucel (ide-cel, Abecma ). Both CAR T-cells target the B-cell maturation antigen (BCMA) and their sequential use is as yet rare, thus data on safety and efficacy of their sequential employment are precious and relevant for the myeloma commmunity.
论文信息
- 作者
- Mobascher P、Engelhardt M、Wäsch R
- 第一作者单位
- Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany.Germany
- 通讯作者单位
- Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany. ralph.waesch@uniklinik-freiburg.de.Germany
- 文献类型
- 病例报告
- 期刊
- Annals of hematology2025 Mar
- 原文标识
- PubMed 40178605 · DOI 10.1007/s00277-025-06340-y
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →